Compare Heron Therapeutics Inc (HRTX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Noble Corporation plc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Noble Corporation plc trades at $42.18 (market cap $6.48B). The key difference: Noble Corporation plc is far larger — about 70.9× Heron Therapeutics Inc's market cap, and Noble Corporation plc pays a 4.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NE | |
|---|---|---|
Market Cap | $91.46M | $6.48B |
Sector | Health | Technology |
52-Week High | $1.96 | $54.37 |
52-Week Low | $0.39 | $25.70 |
Enterprise Value | $189.36M | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Noble Corporation (NE) trades at $40.60, down 2.17% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators. The company maintains solid fundamentals with a $3.29B revenue in 2025 and a net income margin of 7.17%, supported by recent contract wins like the $136.2M Brunei drilling deal. Cash flow remains positive, and a $0.50 dividend was recently declared, payable in June 2026.
The outlook is cautiously optimistic with a consensus price target of $49.75 offering 22.5% upside, though recent earnings misses and competitive pressures in offshore drilling pose risks. Analyst sentiment is divided with 31% buy ratings, reflecting confidence in Noble's high-specification rig fleet and contract backlog, balanced by execution challenges and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
